PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) ACQUIRES REMAINING OUTSTANDING STAKE IN PREDICTIVE THERAPEUTICS, LLC.

Salt Lake City, UT- Predictive Technology Group, Inc. (PRED.OTCPINK) announces that it acquired the remaining minority position in Predictive Therapeutics, LLC.  In March 2015, the Company acquired a majority stake, 84% control, in what is now the Company’s subsidiary, Predictive Therapeutics, LLC.

A 16% minority stake has been acquired, and the Company has full 100% control of its subsidiary, Predictive Therapeutics, LLC.

Brad Robinson, President, Predictive Technology Group, Inc. states, “Even though PRED controlled the subsidiary since March 2015, the acquisition of the remaining 16% gives us full control and provides ease for accounting purposes.”

The website, www.predrx.com, contains information about PRED’s subsidiary, Predictive Therapeutics, LLC’s business of revolutionizing patient care through novel gene-based companion diagnostics and therapeutics.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about this release, contact, Mr. Rich Kaiser, YES INTERNATIONAL, 757-306-3090, yes@yesinternational.com and/or www.predrx.com and/or www.predictivetechnologygroup.com. 

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

NUTROGANICS (NUTT) ANNOUNCES EXECUTIVE CHANGES, STRATEGIC DISCUSSIONS & UPDATES FINANCIAL GUIDANCE

BETHESDA, MD– February 10, 2016 — Nutroganics, Inc. (OTCPINK: NUTT) (“Nutroganics”) announces that it has made some changes to its executive ranks.  Juan Montano has been promoted to Plant Manager of the Company’s NuStar Manufacturing subsidiary, where he has been a long tenured production and business development director. Mike Carnazzo, formerly COO of NuStar, has been terminated for cause. Angela Rataezyk has been promoted to general manager of Nutroganics’ Silverbow Honey subsidiary.  Mrs. Rataezyk is one of Silverbow’s longest tenured employees, having been with the company for over 15 years   Matt Ferguson has departed from the Company.

Nutroganics is investigating certain improper business relationships Mr. Carnazzo appears to have had with at least one customer and their impact on the Company’s business. The Company is discussing the situation with the customer and will make additional disclosures as events merit. The Company is also investigating certain other actions that Mr. Carnazzo took while he was employed by NuStar.  Once the investigations are completed, the Company will announce material findings, and pursue appropriate courses of action including, but not limited to, legal action against the appropriate parties to recover the value compromised by his actions. The Company is working closely with its customers and vendors to repair the damage done by Carnazzo’s actions.

Nutroganics further announces that the Company believes that its 2015 revenue totaled between $11 million and $13 million for the year. Actual 2015 results are expected to be finalized in March and will include Q4 results and may include revisions to prior results to reflect timing and collection issues on receivables. While 2015 revenue exceeded the Company’s original 2015 guidance of $9.5 million issued on September 17, 2014, it falls short of the expected revenue in the Company’s October 29, 2015 press release. The Company’s results are due to poor Q4 performance at NuStar combined with adjustments to the Company’s revenue due to bad receivables.

Nutroganics is modifying its range of expected 2016 revenue from the previous $20-22 million range to a range of $13-20 million.

Nutroganics also announces that it is pursuing discussions with multiple parties regarding potential strategic relationships, including potential mergers and/or reverse mergers. The Company believes that it can better leverage its productive capacity, better serve its customer base, and achieve better liquidity for shareholders as part of a larger Company.

Commenting on the announcements, David Sackler, CEO of Nutroganics said, “We are very disappointed with the breach of fiduciary duty committed by Mike Carnazzo and the actions of at least one of our customers. The purposeful actions translated into our poor Q4 performance. We remain committed, however, to making 2016 an even better year for Nutroganics as we rebuild on a foundation of honesty and trust.  We are intent on maximizing shareholder value and the growth of the business. To that end, we have won numerous new contracts within the last few weeks as clients see a new openness and attitude as a result of Mr. Carnazzo’s removal: a mindset of serving all our clients well, not just a few with preferential access.”

Sackler further states, “We have brought in a significant supply chain partner to work with us on our powders business and are expecting a robust business with them. We raised over $200,000 for new equipment and inventory needs.  The promotions of Juan and Angela to positions of responsibility within the Company have been seamless as a result of their experience and daily, direct involvement with the inner workings of the organization, the customer and vendor base, and the maturation of their skill sets over the years.   Both have significant capability to help the growth of Nutroganics. We look forward to their continued success with the Company.”

About Nutroganics:

Nutroganics, Inc. acquires and grows revenue-generating businesses operating in the healthy lifestyle marketplace, and seeks to capitalize on synergies from manufacturing through distribution. Nutroganics owns Silverbow Honey Company, a producer and packager of honey products founded in 1945 and based in Moses Lake, Washington and NuStar Manufacturing, LLC, a Utah based packager of nutritional products and supplements.

For more information, contact David Sackler at dsackler@nutroganics.com or (240) 223-1000, and/or Rich Kaiser, Investor Relations, YES INTERNATIONAL, rich@yesinternational.com, 757-306-6090, www.nutroganics.com.

Forward-Looking Statements:

This release may contain forward-looking statements, which involve known and unknown risks, uncertainties, and other factors, which may cause Nutroganics’ actual results, performance, or achievements to be materially different from actual future results expressed or implied by the forward-looking statements. Specifically, Nutroganics’ working capital was negatively affected by the actions of Mike Carnazzo and the Company’s 2015 Q4 performance; therefore, the risks which result from lower working capital are heightened. Management undertakes no obligation to update any forward-looking statements after the date of such statements.

Predictive Technology Group, Inc.’s (PRED) Subsidiary Predictive Therapeutics Receives Favorable Ruling from the United States Patent and Trademark Office’s Patent Trial and Appeal Board on Spine Deformity Test and Bio-Implant

Decision may positively impact Company’s pipeline tests and companion treatment technologies

Salt Lake City, UT — (February 02, 2016) – Predictive Technology Group, Inc. (OTC PINK:PRED), a life sciences technology holding company, announced its subsidiary Predictive Therapeutics received a favorable ruling from the United States Patent and Trademark Office’s Patent Trial and Appeal Board (“PTAB”) on its spinal deformity molecular diagnostic tests and companion therapeutics (US Patent application 20150127105).

Mike Schramm, Predictive Therapeutics’ Director of Intellectual Property, said, “We are pleased that the Patent Trial and Appeal Board completely reversed the examiner and tacitly approved all twenty pending claims of the ‘105 application and we now look forward to a speedy allowance.  The claims of the ‘105 application build on previously issued US patents 8,123,787 and 8,641,738 to which ‘105 claims priority and further bolster PRED’s Intellectual Property position.”

Bradley Robinson, PRED’s CEO added, “PRED is excited to move forward with the release of the subsidiary’s, Predictive Therapeutics, spinal deformity tests and begin development work on the companion therapeutics. Predictive Therapeutics is committed to providing our surgeon customers with the highest quality predictive diagnostics and treatment solutions that can ultimately benefit their patients.”

The Company believes that this favorable PTAB decision will have an impact on the other diagnostic tests and companion product candidates that are in our R&D pipeline.

About Predictive Technology Group, Inc.

 Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about this release, contact, Mr. Rich Kaiser, YES INTERNATIONAL 757-306-6090, yes@yesinternational.com and/or www.predrx.com and/or www.predictivetechnologygroup.com.

 Forward-Looking Statements

 To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.